Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...
Vertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and genetic therapies – and has just chalked up fast-track status from the FDA for a cell-based therapy ...
News headlines Vertex Pharmaceuticals (VRTX) is gaining attention with a 25.6% year-over-year earnings growth forecast and strong pipeline advancements, despite concerns over its premium valuation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results